Novo Nordisk (NVO) said Thursday it will move its subcutaneous and oral amycretin candidate for weight management into phase 3 clinical development.
The phase 3 development of the GLP-1 candidate for adults with obesity is based on feedback from regulators on completed clinical trials, according to a statement.
The company said it plans to begin the phase 3 program in Q1 2026.
Shares were up 2.5% in recent trading.
Price: 80.85, Change: +2.12, Percent Change: +2.69
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。